combined detection of RASSF1A and SHOX2 gene methylation was identified as an excellent method for the screening and surveillance of lung cancer that exhibits high sensitivity and specificity
Post-therapeutic SHOX2 and SEPT9 circulating cell-free DNA(ccfDNA) methylation levels correlated with UICC stage (all P <0.01). SEPT9 ccfDNA methylation further allowed for an accurate pre- and post-therapeutic detection of distant metastases.
Data suggest that the microRNA miR-375/short stature homeobox 2 protein (SHOX2) axis may be a novel therapeutic target for esophageal squamous cell carcinoma (ESCC).
We have identified that SHOX2 expression or methylation are potent independent prognostic indicators for predicting LGG patient survival and have potential to identify an important subset of LGG patients with IDHwt status with significantly better overall survival.
Study showed that SHOX2 methylation levels in adenomas and colorectal carcinomas (CRC) were significantly higher compared to those in normal control tissues. Histologic transition from adenomas to CRC was paralleled by amplification of the SEPT9 gene locus.
Whole-genome microarray mRNA-expression profiles of myofibroblasts and skin fibroblasts revealed four additional genes that are significantly differentially expressed in these two cell types: NKX2-3 and LRRC17 in myofibroblasts and SHOX2 and TBX5 in skin fibroblasts
The longitudinal measurement of extracellular plasma mSHOX2 DNA yields information about the response to cytotoxic treatment and allows an early assessment of treatment response for lung cancer patients.
SHOX2 DNA methylation identified 66% of the patients with cancer subsequent to a cytological equivocal diagnosis. SHOX2 complements the cytological diagnosis and the methylation marker panel.
We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.